Browsing by Autor "Jeaneth Velarde"

Now showing 1 - 7 of 7

Allogeneic Hematopoietic Progenitor Cell from Peripheral Whole Blood in Acute Myeloid Leukemia
(Elsevier BV, 2024) Ricardo Amaru; Reyna Mamani; Jeaneth Velarde; Mireya Carrasco; Edgar Teddy Quispe Soto; Silvia Mancilla; Juan Carlos Valencia; Daniela Patón; Ariel Amaru
Acute Myeloid Leukemia (AML) standard treatment involves initial induction therapy administrating two cycles of the 3+7 protocol (3 days anthracycline + 7 days cytarabine), and post-remission therapy of 3 cycles of high-dose cytarabine. The 5-year overall survival is 20 % (PMID: 33734442). During prolonged aplasia, infections and hemorrhages can cause treatment failure and death (PMID: 32236160). That is why transfusions of allogeneic hematopoietic progenitor cells (Allo-HPC) from whole peripheral blood to reduce the time of aplasia and complications were of interest. We studied 6 patients (3 males, 3 females) with AML (M1, M2), average age 35 years (18-60 years), who received Allo-HPC from whole peripheral blood during aplasia after each 3+7 regimen. The transfusion was performed at day 14 (day 12-16) post-regimen, when patients had neutrophils &lt;100/ul (0-100/ul). Regarding donors, one corresponded to HLA identical sibling, and 5 to haploidentical (2 fathers, 2 mothers and 1 brother), they received G-CSF 300 μg subcutaneously every 12 hours over 3 days, then 450 ml phlebotomy was performed. Phlebotomy displayed median WBC 27,310/ul, neutrophils 21,830/ul, CD34+ cells 9/ul, hemoglobin 14.8 g/dl, and platelets 218,000/ul. Thus, whole peripheral blood obtained was transfused through patients' CVC after premedication with dexamethasone 8 mg and metamizole 1 g. FISH (Y chromosome, Vysis CEP-Y DYZ1) and RT-PCR (HUMARA gene) studies were performed for chimerism analysis. Recovery of neutrophils &gt;500/ul was observed at day 9 and platelets &gt;20,000/ul at day 6. One case of cutaneous rush was observed as an adverse event. MRD after each cycle reflected 0.01% average. Three patients remain alive with follow-up of 4 years, 5 years and 1 year respectively. Two patients relapsed and died during 1year follow-up. One patient developed optic neuritis and did not receive high-dose cytarabine therapy, relapsed and died after 6 months. None of the patients presented acute or chronic GVHD. Regarding the results of chimerism, one male patient (1year follow-up) showed mixed chimera by FISH (Y=95%) and by RT-PCR (HUMARA gene), such studies were still in progress in the other two women patients. Contrasting patients who received Allo-HPC from the ones who do not, statistically differences were found in neutrophils recovery and hospital staying, the former displayed 9 + 3 days vs 14 + 4 days (p=0.008) and 19 +5 days vs 25 + 4 days (p=0.009) respectively, infections also decreased from 83% to 25%. Transfusion of Allogeneic Hematopoietic Progenitor Cell from Peripheral whole blood reduces the duration of aplasia, infections, inpatient stays, and increases survival.
ALTAS DOSIS DE COBALAMINA Y ÁCIDO FÓLICO EN EL TRATAMIENTO DE LEUCOPENIAS POST COVID-19
(2021) Ricardo Amaru; Mireya Carrasco; Jeaneth Velarde; Reyna Mamani; Daniela Patón; Julieta Luna
ERITROCITOSIS PATOLÓGICA DE ALTURA: CARACTERIZACIÓN BIOLÓGICA, DIAGNÓSTICO Y TRATAMIENTO
(2013) Ricardo Amaru; Hortencia Miguez; Rosario Peñaloza; Gina Torres; Oscar Vera; Jeaneth Velarde; Nelly Huarachi; Reyna Mamani; Heriberto Cuevas
FILTRO DE AGUA EN LA PREPARACIÓN DE QUIMIOTERAPIA PARA OPTIMIZAR LA BIOSEGURIDAD
(2016) Jeaneth Velarde; Reyna Mamani; Nelly Guarachi; Teddy Quispe; Ricardo Amaru; Heriberto Cuevas
Low incidence of HTLV-1 infection in Andean highlanders with NFKB1 haplotype
(Elsevier BV, 2025) Silvia Mancilla; Luis Malpica; Javier Valencia; Julieta Luna; Rodolfo Urquidi; Alex Chaman; Daniel E. Martínez; Jeaneth Velarde; Ricardo Amaru
Abstract Human T-cell lymphotropic virus type I (HTLV-1) is a retrovirus infecting T-lymphocytes recognized as the causative agent of adult T-cell leukemia/lymphoma (ATL). Approximately 5 % of individuals infected with this virus develop ATL after a prolonged latency period, often several decades (PMID: 36800643). The genome of HTLV-1 involves the regulatory protein Tax which plays a central role in the survival, proliferation, and transformation of HTLV-1-infected cells into malignant cells. By constitutively activating the IKK complex, Tax-1 oncoprotein induces persistent NF-κB activation that drives the proliferation and survival of infected T-cells, thereby contributing to leukemogenesis in ATL (PMID: 29685460). Persistent activation of NF-kB induces canonical and noncanonical pathways that entail a key role for host cell transformation, hence its importance as a target in therapeutics (PMID: 20845110). Reports display that canonical NF-κB activation by Tax would likely be disrupted, impairing key oncogenic mechanisms of HTLV-1 (PMID: 29515558; PMID: 29722927). Concerning NF-κB, it has been reported of a NFKB1 rs230511 haplotype enriched in the Andean population, which entailing an alternative splicing that skips exons 4 and 5 involves a loss of function affecting the functional levels of NFKB1, and inflammatory-related genes (PMID: 39971917). Andean region is known to be endemic for HTLV-1 (PMID: 23162541), therefore in order to elucidate the incidence of HTLV-1 in Andean with NFKB1 haplotype, we performed a screening to normal blood donors and hematologic diseases patients. A total of 462 blood samples were collected from individuals living in the Bolivian Andean region at 4000 meters above sea level where NFKB1 rs230511 haplotype prevalence stand for 95 %, and genotypic frequency corresponds CC 5 %, CT 33%, TT 62% and the allele frequency reflects T=0,88, C=0,12. (Blood, ASH 2316,2018; Hematol Mex 2023; 24(2):52-67). Among the samples, 247 were from normal blood donors (152 females with an average age of 24 years and 95 males with an average age of 32 years), the remaining 215 samples came from patients with hematologic diseases (109 females with average age 51 years and 106 males with average age 53 years). Of these patients, 46 were diagnosed with chronic myeloid leukemia (CML), while 169 had other non-malignant hematologic conditions. All specimens were screened using both the ASSURE HTLV-I/II Rapid Test and HTLV-I/II ELISA 4.0 (MP Biomedicals Asia Pacific). Any reactive samples were subsequently confirmed with a supplementary western blot assay (HTLV BLOT 2.4, MP Biomedicals Asia Pacific). Interestingly, out of 462 specimens, only one tested positive for HTLV-1 (0,22 %). This positive case corresponded to a patient with a hematologic disease who had received massive blood transfusions (&gt;20 units). Results display an extremely low HTLV-1 Incidence in Bolivian Andean region compared to other ethnic groups where prevalence exceeds 10%. This low incidence may be related to the fact that approximately 95% of the Andean population carries a nonfunctional NFKB1 haplotype, potentially limiting HTLV-1 pathogenesis. Further studies focusing anti-HTLV-1 antibody responses in individuals with NFKB1 deletion are needed to understand the molecular mechanism concerned.
MECANISMO MOLECULAR DE LAS ESTATINAS EN EL TRATAMIENTO DE LA ERITROCITOSIS PATOLÓGICA DE ALTURA
(2013) Ricardo Amaru; Oscar Arturo Vera; Hortencia Miguez; Rosario Peñaloza; Gina Torres; Jeaneth Velarde; Helly Huarachi; Reyna Mamani; Heriberto Cuevas
TRATAMIENTO DE LA ERITROCITOSIS SECUNDARIA EN LA ALTURA
(2020) Ricardo Amaru; Jeaneth Velarde; Reyna Mamani; Mireya Carrasco; Daniela Patón; Ariel Amaru